electroCore, Inc.

**electroCore, Inc.**

electroCore develops and commercializes non-invasive vagus nerve stimulation (nVNS) technology for the treatment of headache disorders and general wellness applications. The company's primary product is gammaCore, a prescription handheld device for acute treatment of migraine and episodic cluster headache, as well as hemicrania continua and paroxysmal hemicrania. The company also offers gammaCore Sapphire, a portable, rechargeable variant designed for multiple primary headache conditions.

Beyond prescription medical devices, electroCore markets consumer wellness products under the Truvaga brand, including Truvaga 350 and Truvaga Plus, an app-enabled device intended for general wellness use. The company also provides TAC-STIM for human performance applications. These products represent the company's expansion into the consumer bioelectronic wellness market alongside its core prescription device business.

electroCore operates primarily in the United States, with commercial presence in the United Kingdom and international markets. The company is a relatively small manufacturer with 73 full-time employees and maintains headquarters in Rockaway, New Jersey. As a medical device manufacturer, the company's revenue streams derive from prescription device sales, consumer wellness product sales, and related services.